Jan 7, 2026 | Main Page Post, Rejuvenair, SPRAY-CB
SPRAY-CB met its primary endpoint and multiple secondary endpoints with statistical significance, FDA review underway BOSTON, Jan. 7, 2026 /PRNewswire/ — CSA Medical, Inc., a medical device company focused on interventional pulmonary therapies, today...
Oct 8, 2024 | Main Page Post, Product News, Rejuvenair, SPRAY-CB
Underlying proof of rejuvenative healing indicative of airway remodeling corresponds with clinical efficacy and improved quality of life Boston, MA—Oct 8, 2024: /PRNewswire/ — CSA Medical, Inc., a leader in developing spray cryotherapy solutions for the...
Feb 7, 2024 | Main Page Post, Rejuvenair, SPRAY-CB
The RejuvenAir System is a minimally invasive medical device therapy which aims to target the underlying cause of COPD with Chronic Bronchitis BOSTON, Feb. 7, 2024 /PRNewswire/ — CSA Medical Inc., a developer of medical devices advancing the power of liquid...
May 13, 2021 | Main Page Post, Product News, Rejuvenair, SPRAY-CB
These results should provide the scientific proof behind the remodeling response and clinical improvements identified in earlier studies Boston, MA—May 12, 2021: CSA Medical, Inc., today announced ® that all subjects have been enrolled in the RejuvenAir System study...
Apr 19, 2021 | Main Page Post, Product News, Rejuvenair, SPRAY-CB
Boston, MA –April 19, 2021: CSA Medical, Inc., today announced that Wissam Abouzgheib, MD, chief of pulmonary medicine at Cooper University Health Care, Camden, New Jersey, has joined the SPRAY-CB Study investigating a new device treatment for COPD with Chronic...
Oct 22, 2020 | Main Page Post, SPRAY-CB
The SPRAY-CB trial marks the first pivotal study of a medical device therapy targeting the underlying cause of Chronic Bronchitis. Boston,MA. – October 22, 2020: CSA Medical Inc., a developer of medical devices advancing the power of liquid nitrogen spray cryotherapy,...
